Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

被引：113

作者：

Lee, So Yun ^{[1
]}

Kang, Moon Sung ^{[2
]}

Jeong, Woo Yeup ^{[1
]}

Han, Dong-Wook ^{[2
]}

Kim, Ki Su ^{[1
]}

机构：

[1] Pusan Natl Univ, Coll Engn, Dept Organ Mat Sci & Engn, 2 Busandaehak Ro 63 Beon Gil, Busan 46241, South Korea

[2] Pusan Natl Univ, Coll Nanosci & Nanotechnol, Dept Cognomechat Engn, 2 Busandaehak Ro 63 Beon Gil, Busan 46241, South Korea

来源：

CANCERS | 2020年 / 12卷 / 04期

基金：

新加坡国家研究基金会;

关键词：

hyaluronic acid; cancer therapy; anticancer agent; theranosis; nanomedicine; receptors; TYRAMINE HYDROGEL SYSTEM; REDUCED GRAPHENE OXIDE; ANTICANCER DRUG; GOLD NANOPARTICLES; MULTIFUNCTIONAL NANOPARTICLES; INTRACELLULAR DELIVERY; LUNG-CANCER; CD44; DOXORUBICIN; MICELLES;

D O I：

10.3390/cancers12040940

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hyaluronic acid (HA) is a natural mucopolysaccharide and has many useful advantages, including biocompatibility, non-immunogenicity, chemical versatility, non-toxicity, biodegradability, and high hydrophilicity. Numerous tumor cells overexpress several receptors that have a high binding affinity for HA, while these receptors are poorly expressed in normal body cells. HA-based drug delivery carriers can offer improved solubility and stability of anticancer drugs in biological environments and allow for the targeting of cancer treatments. Based on these benefits, HA has been widely investigated as a promising material for developing the advanced clinical cancer therapies in various formulations, including nanoparticles, micelles, liposomes, and hydrogels, combined with other materials. We describe various approaches and findings showing the feasibility of improvement in theragnosis probes through the application of HA.

引用

页数：17

共 109 条

[1]

Alaqad K., 2016, J ENV ANAL TOXICOL, V6, P525, DOI [10.4172/2161-0525.1000384, DOI 10.4172/2161-0525.1000384]

[2]

[Anonymous], 2016, APPL SCI

[3]

[Anonymous], WORLD CANC REPORT 20

[4] Hyaluronic Acid Conjugates as Vectors for the Active Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment [J].